Fortrea Holdings (FTRE) Free Cash Flow (2022 - 2026)
Fortrea Holdings (FTRE) posted Free Cash Flow of -$25.0 million for Q1 2026, down 120.56% on a QoQ basis from $121.6 million in Q4 2025, and up 80.33% year-over-year from -$13.9 million in Q1 2025.
Fortrea Holdings (FTRE) Free Cash Flow (2022 - 2026) Analysis & Trends
Fortrea Holdings' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$25.0 million for Q1 2026.
- Quarterly Free Cash Flow rose 80.33% year-over-year to -$25.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.4 million (up 31.22% YoY) and the FY2025 annual result came in at $88.3 million, down 62.79% from the prior year.
- Free Cash Flow was -$25.0 million for Q1 2026 at Fortrea Holdings, down from $121.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $262.5 million in Q2 2024 and bottomed at -$127.1 million in Q1 2025.
- A 5-year average of $33.2 million and a median of $9.0 million in 2023 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 850.0% in 2025, while the deepest fall reached 264.18% in 2025.
- Fortrea Holdings' Free Cash Flow stood at $5.1 million in 2022, then surged by 76.47% to $9.0 million in 2023, then soared by 125.56% to $20.3 million in 2024, then soared by 499.01% to $121.6 million in 2025, then tumbled by 120.56% to -$25.0 million in 2026.
- Business Quant data shows FTRE's Free Cash Flow at -$25.0 million in Q1 2026, $121.6 million in Q4 2025, and $79.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | -25.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.00 Mn |
| Mar 31, 2026 | -25.00 Mn |
| Dec 31, 2025 | 121.60 Mn |
| Dec 31, 2025 | 121.60 Mn |
| Sep 30, 2025 | 79.50 Mn |
| Sep 30, 2025 | 79.50 Mn |
| Jun 30, 2025 | 14.30 Mn |
| Jun 30, 2025 | 14.30 Mn |
| Mar 31, 2025 | -127.10 Mn |
| Mar 31, 2025 | -127.10 Mn |
| Dec 31, 2024 | 20.30 Mn |
| Dec 31, 2024 | 20.30 Mn |
| Sep 30, 2024 | -10.60 Mn |
| Sep 30, 2024 | -10.60 Mn |
| Jun 30, 2024 | 262.50 Mn |
| Jun 30, 2024 | 262.50 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Dec 31, 2023 | 9.00 Mn |
| Dec 31, 2023 | 9.00 Mn |